On Wednesday, Goldman Sachs reiterated its Buy rating on Viridian Therapeutics (NASDAQ:VRDN) with a steady price target of $25.00. The affirmation comes in light of recent strategic moves by a competitor in the thyroid eye disease (TED) treatment market. The competitor, which Goldman Sachs does not cover, announced on Tuesday that it will prioritize its drug lonigutamab for TED, discontinuing other projects and reducing its workforce by 33% to extend its cash runway to mid-2027.
This competitor's early proof-of-concept data for lonigutamab was released in March 2024, demonstrating results from a Phase 1/2 trial. Despite the competitive pressure, Goldman Sachs believes that Viridian Therapeutics' VRDN-003, with its half-life extension and autoinjector properties, holds commercial advantages and the potential to be best-in-class among subcutaneous TED programs.
Viridian Therapeutics' rival has also decided to skip a Phase 2b/3 study, opting to proceed directly to Phase 3 development by the first quarter of 2025. Topline Phase 3 results are anticipated in 2026, with a Biologics License Application (BLA) filing to follow. Specific details of the Phase 3 study design have not been disclosed, but an end-of-Phase 2 meeting with the FDA is planned for later this year, along with an investor meeting to discuss Phase 2 data updates and Phase 3 design, including dose selection.
The strategic shift by Viridian Therapeutics' competitor to expedite its drug development could intensify the race to market. However, Goldman Sachs' analyst suggests that Viridian's VRDN-003 may maintain an edge due to its unique drug delivery and formulation attributes.
In other recent news, Viridian Therapeutics has been maintaining positive momentum in its clinical trials. The company has successfully completed patient enrollment for its Phase 3 trial of VRDN-001 for active thyroid eye disease (TED), with top-line results anticipated in September 2024. Analyst firms, including Goldman Sachs, RBC Capital, and Wolfe Research, have reiterated their positive outlook on Viridian, projecting potential revenue from VRDN-001 to reach approximately $690 million worldwide by 2027.
Additionally, Viridian's subcutaneous VRDN-003 program is set to enter pivotal trials following a positive Type C meeting with the FDA. The company also plans to submit a Biologics License Application (BLA) for VRDN-001 in the second half of 2025.
Furthermore, Viridian is expected to initiate two critical trials, REVEAL-1 and REVEAL-2, for VRDN-003 in August 2024. These trials aim to test different dosing regimens for the treatment of both active and chronic TED patients.
InvestingPro Insights
As Viridian Therapeutics (NASDAQ:VRDN) continues to make strides in the competitive thyroid eye disease treatment market, insights from InvestingPro provide a nuanced view of the company's financial health and market position. With a market capitalization of $902.13 million, the company holds a noteworthy cash position, as indicated by one of the InvestingPro Tips, which states that Viridian holds more cash than debt on its balance sheet. This could be a significant factor for investors considering the financial stability and long-term viability of the company.
Additionally, the InvestingPro Data reveals a challenging financial landscape for Viridian, with a negative P/E ratio of -3.41, reflecting the company's current lack of profitability. The gross profit margin stands at an alarming -57041.32%, and the company has experienced a substantial revenue decline of -80.41% over the last twelve months as of Q2 2024. These metrics underscore the importance of Viridian's strategic moves in the market, as they navigate through a period of financial pressure.
While Viridian's financials show areas of concern, the company's strategic positioning with its VRDN-003 therapy could offer a competitive edge as suggested by Goldman Sachs. For those interested in a deeper analysis, there are additional InvestingPro Tips available, offering a comprehensive look at Viridian's financial metrics and market potential. These further insights can be accessed through the InvestingPro platform, which provides a robust set of tools for investors looking to make informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.